scholarly journals Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow‐derived mesenchymal stem/stromal cells

Author(s):  
Liem Thanh Nguyen ◽  
Duc M. Hoang ◽  
Kien T. Nguyen ◽  
Duc M. Bui ◽  
Hieu T. Nguyen ◽  
...  
Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S82 ◽  
Author(s):  
P. Adorable-Wagan ◽  
S. Bernal ◽  
D. Lavilles ◽  
M. De Vera

2016 ◽  
Vol 3 ◽  
pp. 87-87 ◽  
Author(s):  
Tarek Wehbe ◽  
Nassim Abi Chahine ◽  
Salam Sissi ◽  
Isabelle Abou-Joaude ◽  
Louis Chalhoub

2009 ◽  
Vol 18 (10) ◽  
pp. 1407-1416 ◽  
Author(s):  
Anil Bhansali ◽  
Vimal Upreti ◽  
N. Khandelwal ◽  
N. Marwaha ◽  
Vivek Gupta ◽  
...  

2020 ◽  
Vol 29 ◽  
pp. 096368972090462
Author(s):  
Gongchi Li ◽  
Han Peng ◽  
Shen Qian ◽  
Xinhua Zou ◽  
Ye Du ◽  
...  

Numerous studies have proposed the transplantation of mesenchymal stem cells (MSCs) in the treatment of typical type 2 diabetes mellitus (T2DM). We aimed to find a new strategy with MSC therapy at an early stage of T2DM to efficiently prevent the progressive deterioration of organic dysfunction. Using the high-fat-fed hyperinsulinemia rat model, we found that before the onset of typical T2DM, bone marrow-derived MSCs (BM-MSCs) significantly attenuated rising insulin with decline in glucose as well as restored lipometabolic disorder and liver dysfunction. BM-MSCs also favored the histological structure recovery and proliferative capacity of pancreatic islet cells. More importantly, BM-MSC administration successfully reversed the abnormal expression of insulin resistance-related proteins including GLUT4, phosphorylated insulin receptor substrate 1, and protein kinase Akt and proinflammatory cytokines IL-6 and TNFα in liver. These findings suggested that MSCs transplantation during hyperinsulinemia could prevent most potential risks of T2DM for patients.


2019 ◽  
Vol 6 (4) ◽  
pp. 3140
Author(s):  
Phuong Thi-Bich Le ◽  
Nguyen Phu-Van Doan ◽  
Phan Van Tien ◽  
Dang Ngo Chau Hoang ◽  
Ngoc Kim Phan ◽  
...  

In the previous publication with title ”A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report”1, page 2968, in the Table 1, the unit for fasting blood glucose and blood glucose 2 hours after meals is mg/dL; however, the corrected unit for fasting blood glucose and blood glucose 2 hours after meal is mmol/L.  


Sign in / Sign up

Export Citation Format

Share Document